Results 171 to 180 of about 99,805 (324)

Polypharmacy and Drug Interactions in the COVID-19 Pandemic [PDF]

, 2023
Ricardo E Barcia, Guillermo Alberto Keller, Natalia Bello, Francisco Azzato, Roberto A. Díez, Guido Giunti   +5 more
openalex   +1 more source

Bexicaserin for the treatment of seizures in developmental and epileptic encephalopathies: A phase 1b/2a trial (PACIFIC)

Epilepsia, EarlyView.
Abstract Objective This randomized, double‐blind, phase 1b/2a clinical trial was designed to evaluate the safety, tolerability, and efficacy of oral bexicaserin versus placebo for the treatment of seizures in adolescents and adults with developmental and epileptic encephalopathies (DEEs).
Dennis J. Dlugos, Ingrid E. Scheffer, Jacqueline A. French, David G. Vossler, Chad Orevillo, Shikha Polega, Randall Kaye, and the LP352‐201 Study Investigators, Kore Liow, Ena Zhu, Jennifer Waldron, Hayley Groubert, Alexis Anderson, Pavel Klein, Salman Hashmi, Shicong Ye, Anita Farhi, David Vossler, Dione M. Froman, Shannon L. Hoffman‐Huffaker, Ki Hyeong Lee, AnnaLyn Dallas, Amir Arain, Laura Beeler, Michael Macken, Irena Bellinski, Elizabeth Cunningham, James Renfroe, Shezsay Colbert, Robert Hogan, Patty Schaefer, Susan Shaw, Sheetal Desai, Ahmed Sadek, Haile Robertson, Kamil Detyniecki, Anabela Cieslicki, Ruben Kuzniecky, Sarah Goodman, Selim Benbadis, Marina Azevedo, Sami Aboumatar, Julie Biel, Nilika Singhal, Emerald Wan, Evan Fertig, Hannah Hart, Debopam Samanta, Sarah Hankins, Steven Wolf, Patricia Pena, Robert Nahouraii, M. J. Mari, David Burdette, Stephanie Mueller, Karen Keough, Victoria Henderson, Talitha Durgin, Terence O’Brien, Rafael Smith, Jack Germaine, Kate Riney, Lori Anthony, David Reutens, Kimberley Irwin, Michael Fahey, Melissa Batt, Stephanie Kaladis, Kasthoori Jeyachanthiran, Ingrid Scheffer, Rebecca Wharrie, Greesha Zacharia, Brittany Walsh, Heather Robinson, Sharon Ganter   +74 more
wiley   +1 more source

Polypharmacy overdose (Mesalazine)

, 2017
Sachintha Hapugoda
openalex   +1 more source

Anti‐seizure medications in patients with post‐stroke epilepsy: A survival analysis study

Epilepsia, EarlyView.
Abstract Objective The role of antiseizure medications (ASMs) in patients with post‐stroke epilepsy (PSE) is still debated. Although a few studies have compared the efficacy of different ASMs on mortality in patients with PSE, overall evidence on the impact of ASM use on survival is limited.
Ippazio Cosimo Antonazzo, Carla Fornari, Gabriele Buongarzone, Pietro Ferrara, Giacomo Crotti, Alberto Zucchi, Paolo Angelo Cortesi, Davide Rozza, Lorenzo Giovanni Mantovani, Giampiero Mazzaglia   +9 more
wiley   +1 more source

Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

, 2019
Katie Bechman, Benjamin D Clarke, Andrew I Rutherford, Mark Yates, Elena Nikiphorou, Mariam Molokhia, Sam Norton, Andrew P. Cope, Kimme L Hyrich, James Galloway   +9 more
openalex   +2 more sources

Impact of long‐term treatment with cenobamate on concomitant usage of antiseizure medications: A real‐world retrospective study in Spain

Epilepsia, EarlyView.
Abstract Objectives This study explored the safety and effectiveness of adjunctive cenobamate (CNB) in patients with different levels of drug‐resistant epilepsy (DRE) in a real‐world setting, including its impact on the use of co‐antiseizure medication (co‐ASM). Methods This was a single‐center, retrospective, observational study.
Juan María Sánchez‐Caro, Roshan Hariramani Ramchandani, Iratxe Maestro Saiz, Juan Jesús Rodríguez Uranga   +3 more
wiley   +1 more source

Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison

, 2013
Daeyoung Roh, Jhin Goo Chang, Chan‐Hyung Kim, Hyun Sang Cho, Suk Kyoon An, Young‐Chul Jung   +5 more
openalex   +2 more sources

Cognitive stagnation and executive function deficits in young children with SCN1A+ Dravet syndrome: Detailed characterization of onset, progression, and impact in the ENVISION natural history study

Epilepsia, EarlyView.
Abstract Objective Dravet syndrome (DS) is a developmental and epileptic encephalopathy characterized by drug‐resistant seizures and developmental slowing. Although cognitive and executive function deficits have been described, their early trajectory is not well understood.
Joseph Sullivan, M. Scott Perry, Ingrid E. Scheffer, James Wheless, Susana Boronat, Andreas Brunklaus, Linda Laux, Anup D. Patel, Colin Roberts, Dennis Dlugos, Deborah Holder, Kelly Knupp, Matt Lallas, Steven Phillips, Eric Segal, Dennis Lal, Elaine Wirrell, Sameer Zuberi, Gerard Gioia, Rebecca Shaffer, Madison M. Berl, Mary Wojnaroski, Sarah Christensen, Alexander King, Emma S. James, Maria Candida Vila, Norman Huang, Jacqueline S. Gofshteyn, Salvador Rico   +28 more
wiley   +1 more source

Characterizing Medicare Medication Therapy Management program enrollees with central nervous system-active polypharmacy. [PDF]

J Manag Care Spec Pharm
Hung A, Wilson LE, Smith VA, Erickson R, Tharpe K, Brandt N, Anderson TS, Valdez O, Castora-Binkley M, Pavon J, Hastings SN, Maciejewski ML, Sloan CE.   +12 more
europepmc   +1 more source

The hidden magnitude of polypharmacy: using defined daily doses and maximum licensed daily doses to measure antipsychotic load

, 2019
My Linh Nguyen, Bruce Sunderland, Stephen Lim, Laetitia Hattingh, Leanne Chalmers   +4 more
openalex   +2 more sources